摘要
磷脂酰肌醇3-激酶（PDK）信号通路已成为近年来的研究热点,该信号通路下游主要为蛋白激酶B（Akt）及哺乳动物西罗莫司靶蛋白（mTOR）.PI3K/Akt/mTOR信号通路广泛存在于各种细胞中,其作为细胞内重要的抗凋亡、促生存的信号通路,在调节细胞生长、增殖、凋亡、存活和迁移中起重要作用.与此同时,该通路参与调控许多重要的细胞进程,并且与肿瘤、肥胖、2型糖尿病、神经退行性疾病、癫（痫）等病理情况有关.结节性硬化复合物（TSC）1/2或第10号染色体缺失的磷酸酶和张力蛋白同源物（PTEN）的突变或环境刺激等可刺激mTOR依赖的蛋白质合成,导致细胞形态和功能的异常,产生相应临床症状.因此,研究mTOR信号通路在癫（痫）中的作用,探讨干预和治疗措施具有重要的临床意义.现就PI3K/Akt/mTOR信号通路的结构组成、生理学功能及癫（痫）相关的信息进行阐述.
Study of the phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt）/mammalian target of rapamycin （mTOR） signaling pathway has been becoming more and more popular.This pathway widely exists in kinds of cells of human being.As one main anti-apoptic and enhancing survival pathway in cells, it plays an important role in cellular growth （increased cell size）, proliferation （increased cell number）, apoptosis, cell survival and migration.At the same time,the pathway regulates many major cellular processes and is implicated in an increasing number of pathological conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration disease, epilepsy.In recent years,many studies have shown that the dysfunction of PI3K/Akt/mTOR signaling pathway can lead to neurodevelopmental disease.Loss of tuberous sclerosis complex （TSC）1/2 or phosphatase ad tensin homologue deleted on chromosome 10 （PTEN）, or environmental stimuli such as inflammation, epilepsy, or hypoxia may stimulate mTOR-dependent protein synthesis,resulting in a host of cellular, structural, and physiological responses that culminate in clinical symptoms.Study the role of mTOR signaling pathway in early-onset epileptic encephalopathy, discuss the intervention and therapy in early-onset epileptic encephalopathy have important clinical meanings.In this article, the components, physiological functions,information were elucidated relative to the PI3 K/Akt/mTOR signaling pathway, and the interaction of the signaling pathway and epilepsy was discussed.
出处
《中华实用儿科临床杂志》
CSCD
北大核心
2015年第24期1915-1917,共3页
Chinese Journal of Applied Clinical Pediatrics
基金
国家自然科学基金（81200998）
国家科技支撑计划项目（2012BA103800）
北京市自然科学基金（7111213,7092105）
卫生部临床学科重点项目（2010-12）
